Life Sciences Licensee Company of the Year

RxKinetix™, Inc., located in Louisville, CO, is a specialty pharmaceutical company focused on developing new therapeutics for oncology care. By combining proven drugs with its proprietary, polymer-based drug delivery technologies, RxKinetix has accelerated development timelines while significantly reducing the risk of failure. Currently four products are in development, including some that incorporate technology from the CU-Boulder Department of Chemical and Biological Engineering and the CU-Denver and Health Sciences Center Department of Pharmaceutical Sciences.

RxKinetix has received numerous grants including from SBIR, STTR, and the Foundation for the National Institutes of Health. More recently it has received a prestigious grant for its vaccines program from the Grand Challenges in Global Health initiative funded in part by the Bill and Melinda Gates Foundation. RxKinetix's grant is based on the Grand Challenge #2 entitled "*Prepare vaccines that do not require refrigeration*". The project initially targets eliminating the cold chain requirement for measles and hepatitis B vaccines. Marazban Sarkari, Ph.D., is Principal Investigator for the Grand Challenges Grant.

Under the Grand Challenges grant, RxKinetix will collaborate with Indian Immunologicals Limited (IIL) in the development of thermostable Hepatitis B vaccines with improved stability at non-refrigerated temperatures. ILL, founded in 1983 by the Indian dairy industry to manufacture vaccine, is the fifth largest player in the animal health market in India and the market leader in veterinary vaccines. As part of the collaboration, ILL will supply RxKinetix with Hepatitis B vaccine, which will be formulated by RxKinetix in its ProJuvant™ vaccine delivery platform and tested for thermostability. Formulations showing good potential will then be tested in vivo.

RxKinetix announced completion in October of their Phase 2 clinical trial of RK-0202 in oral mucositis, the primary rate-limiting side effect associated with radiation and chemotherapy. The Independent Data Monitoring Committee (IDMC) for the Phase 2 trial recommended stopping enrollment in order to expedite development of the drug. The IDMC found no significant safety issues associated with the use of RK-0202. Two other products are targeting proctitis and oral pain and could potentially be filed as Investigational New Drugs with the FDA in early 2006. In addition, the company is developing a hematopoietic growth factors formulation, HemaGel™G-CSF and vaccines with improved release and temperature stability characteristics.

Harry Ross, MD, President and CEO, has been with RxKinetix since 1999. Retired from clinical practice, he is a general partner in Aweida Ventures Management, an independent Colorado investing fund that focuses on high-tech and health related ventures. Dr. Ross received his Doctor of Medicine degree from Oregon Health Sciences University and he has post-graduate training in surgery and emergency medicine with board certification in emergency medicine.
www.rxkinetix.com

Physical Sciences/Engineering/Information Technology Licensee Company of the Year

Phiar Corporation is an early stage company applying the concepts of metal-insulator nanotechnology to terahertz-wave and ultra-high-speed electronic components. The result is a breakthrough platform technology that lends itself to multiple applications, including high-speed computing and communications, and the emerging field of terahertz imaging. Phiar has developed an extensive patent portfolio.

During the late 1990s, Garret Moddel (Professor, Electrical and Computer Engineering at CU-Boulder) and his Ph.D. student, Blake Eliasson, worked on a very different solar cell technology. Blake found a way to make a radical improvement in the technology that transformed it from a research project to a practical technology. As they worked with the technology, it became apparent to the inventors that because of its monolithic integratability onto any substrate, ultra-high speed, and broad wavelength, the technology offered the potential to significantly boost data rates for wireless communications and provide higher resolution for radar and imaging applications. Together with Mike Estes, a highly innovative former student of Garret's, Moddel and Eliasson formed Phiar Corporation. Phiar sought and received funding from the government and then from Menlo Ventures, and opened its doors in July, 2001.

In August of this year, Phiar announced a Joint Development Agreement with Motorola for the continuing development of its high frequency (THz) metal-insulator technology for next generation electronic devices. The next generation receive arrays are expected to be low cost with the ability to be incorporated into multiple high-speed applications including Device-to-Device wireless communications and Personal Consumer Near Field Communications (NFC) as well as Medical Imaging, Automotive Radar, Homeland Security Scanning, and

Defense applications. Motorola and Phiar plan to demonstrate circuits that are capable of running in the hundreds of GHz and potentially into the THz range.

Phiar's metal-insulator technology can be broadly incorporated with standard integrated circuits manufacturing as well as other semiconductor and printed circuit technologies. Because the technology is compatible with multiple standards and substrates, it has the potential to greatly improve the speed and simplify interconnects, both lowering cost and improving performance. The technology has the potential to provide the marketplace with consumer devices which can run at significantly higher data rates (tens of Gbps) as compared to other wireless solutions such as Bluetooth and Ultra-Wideband which operate in the low to hundreds of Mbps. The Phiar-Motorola collaboration will focus on technology development as well as the follow-on industry adoption and standardization work that is required to make the potential THz solution accepted commercially on a worldwide basis.

This year Phiar hired a new President & CEO, Bob Goodman, and closed an A-3 round of funding for $6.3 million from Menlo Ventures, a top-tier venture capital firm in Northern California. Phiar has also successfully completed two contracts from the Defense Advanced Research Projects Agency (DARPA) and is in the process of reviewing a new Phase II DARPA project.

Bob Goodman came to Phiar from senior management in the semiconductor industry, including roles as CEO of Luxtron Corporation and CEO of Kentron Technologies. Garret Moddel is Phiar's Chairman and Chief Technology Officer, and Blake Eliasson is Director of Engineering.

www.phiar.com